You are here

Clinical Trials

Only some doses are noninferior to morphine
Treatments show similar efficacy, safety, and tolerability profiles
Annualized relapse rate reduced compared with interferon beta-1a
Committee sees “virtually no chance” of a positive effect
Data show noninferiority to darunavir
Microneedles deliver subcutaneous zolmitriptan
FDA application expected to be submitted by June
Study positions Xarelto for new indication
Phase 3 results cast doubt on 5-HT6 receptor inhibitors
Cleveland medical center treats 39-year-old man